[1]
Robinson PC, Dalbeth N. Febuxostat for the treatment of hyperuricaemia in gout. Expert opinion on pharmacotherapy. 2018 Aug:19(11):1289-1299. doi: 10.1080/14656566.2018.1498842. Epub 2018 Jul 19
[PubMed PMID: 30024787]
Level 3 (low-level) evidence
[2]
. Febuxostat (Uloric) for chronic treatment of gout. The Medical letter on drugs and therapeutics. 2009 May 18:51(1312):37-8
[PubMed PMID: 19448587]
Level 3 (low-level) evidence
[3]
Takano Y, Hase-Aoki K, Horiuchi H, Zhao L, Kasahara Y, Kondo S, Becker MA. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life sciences. 2005 Mar 4:76(16):1835-47
[PubMed PMID: 15698861]
[4]
White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L, CARES Investigators. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. The New England journal of medicine. 2018 Mar 29:378(13):1200-1210. doi: 10.1056/NEJMoa1710895. Epub 2018 Mar 12
[PubMed PMID: 29527974]
[5]
Alqurashi RM, Tamim HH, Alsubhi ZD, Alzahrani AA, Tashkandi E. Tumor Lysis Syndrome in Patients With Solid Tumors: A Systematic Review of Reported Cases. Cureus. 2022 Oct:14(10):e30652. doi: 10.7759/cureus.30652. Epub 2022 Oct 25
[PubMed PMID: 36439565]
Level 1 (high-level) evidence
[6]
McBride A, Trifilio S, Baxter N, Gregory TK, Howard SC. Managing Tumor Lysis Syndrome in the Era of Novel Cancer Therapies. Journal of the advanced practitioner in oncology. 2017 Nov-Dec:8(7):705-720
[PubMed PMID: 30333933]
[7]
Khosravan R, Grabowski BA, Wu JT, Joseph-Ridge N, Vernillet L. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clinical pharmacokinetics. 2006:45(8):821-41
[PubMed PMID: 16884320]
[8]
Osada Y, Tsuchimoto M, Fukushima H, Takahashi K, Kondo S, Hasegawa M, Komoriya K. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. European journal of pharmacology. 1993 Sep 14:241(2-3):183-8
[PubMed PMID: 8243554]
[9]
Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. The Journal of rheumatology. 2009 Jun:36(6):1273-82. doi: 10.3899/jrheum.080814. Epub 2009 Mar 13
[PubMed PMID: 19286847]
[10]
Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, Lioté F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T. 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the rheumatic diseases. 2017 Jan:76(1):29-42. doi: 10.1136/annrheumdis-2016-209707. Epub 2016 Jul 25
[PubMed PMID: 27457514]
[11]
Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. American journal of therapeutics. 2005 Jan-Feb:12(1):22-34
[PubMed PMID: 15662289]
[12]
Gray CL, Walters-Smith NE. Febuxostat for treatment of chronic gout. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2011 Mar 1:68(5):389-98. doi: 10.2146/ajhp100394. Epub
[PubMed PMID: 21330679]
[13]
Hu M, Tomlinson B. Febuxostat in the management of hyperuricemia and chronic gout: a review. Therapeutics and clinical risk management. 2008 Dec:4(6):1209-20
[PubMed PMID: 19337428]
[14]
Ikemura K, Hiramatsu SI, Shinogi Y, Nakatani Y, Tawara I, Iwamoto T, Katayama N, Okuda M. Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein. Scientific reports. 2019 Dec 30:9(1):20359. doi: 10.1038/s41598-019-56900-2. Epub 2019 Dec 30
[PubMed PMID: 31889141]
[15]
Edwards NL. Febuxostat: a new treatment for hyperuricaemia in gout. Rheumatology (Oxford, England). 2009 May:48 Suppl 2():ii15-ii19. doi: 10.1093/rheumatology/kep088. Epub
[PubMed PMID: 19447778]
[16]
Bruce SP. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. The Annals of pharmacotherapy. 2006 Dec:40(12):2187-94
[PubMed PMID: 17132810]
[17]
Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis and rheumatism. 2008 Nov 15:59(11):1540-8. doi: 10.1002/art.24209. Epub
[PubMed PMID: 18975369]
Level 1 (high-level) evidence
[18]
Jackson RL, Hunt B, MacDonald PA. The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age. BMC geriatrics. 2012 Mar 21:12():11. doi: 10.1186/1471-2318-12-11. Epub 2012 Mar 21
[PubMed PMID: 22436129]
[19]
FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, Gelber AC, Harrold LR, Khanna D, King C, Levy G, Libbey C, Mount D, Pillinger MH, Rosenthal A, Singh JA, Sims JE, Smith BJ, Wenger NS, Bae SS, Danve A, Khanna PP, Kim SC, Lenert A, Poon S, Qasim A, Sehra ST, Sharma TSK, Toprover M, Turgunbaev M, Zeng L, Zhang MA, Turner AS, Neogi T. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis care & research. 2020 Jun:72(6):744-760. doi: 10.1002/acr.24180. Epub 2020 May 11
[PubMed PMID: 32391934]
[20]
Pierre K, Gomez NF, Canha C, Masri G. Gout in Pregnancy: A Rare Phenomenon. Cureus. 2020 Nov 25:12(11):e11697. doi: 10.7759/cureus.11697. Epub 2020 Nov 25
[PubMed PMID: 33391930]
[22]
Schumacher HR Jr, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford, England). 2009 Feb:48(2):188-94. doi: 10.1093/rheumatology/ken457. Epub
[PubMed PMID: 19141576]
[23]
Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, Lademacher C. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis research & therapy. 2010:12(2):R63. doi: 10.1186/ar2978. Epub 2010 Apr 6
[PubMed PMID: 20370912]
[24]
Tsai M, Wu JT, Gunawardhana L, Naik H. The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline. International journal of clinical pharmacology and therapeutics. 2012 May:50(5):331-7
[PubMed PMID: 22541837]
[25]
Komatsu H, Enomoto M, Shiraishi H, Morita Y, Hashimoto D, Nakayama S, Funakoshi S, Hirano S, Terada Y, Miyamura M, Fujimoto S. Severe hypoglycemia caused by a small dose of repaglinide and concurrent use of nilotinib and febuxostat in a patient with type 2 diabetes. Diabetology international. 2020 Oct:11(4):388-392. doi: 10.1007/s13340-020-00434-w. Epub 2020 Apr 8
[PubMed PMID: 33088647]
[26]
Lehtisalo M, Keskitalo JE, Tornio A, Lapatto-Reiniluoto O, Deng F, Jaatinen T, Viinamäki J, Neuvonen M, Backman JT, Niemi M. Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin. Clinical and translational science. 2020 Nov:13(6):1236-1243. doi: 10.1111/cts.12809. Epub 2020 May 26
[PubMed PMID: 32453913]
[27]
Di Rienzo T, D'Angelo G, D'Aversa F, Campanale MC, Cesario V, Montalto M, Gasbarrini A, Ojetti V. Lactose intolerance: from diagnosis to correct management. European review for medical and pharmacological sciences. 2013:17 Suppl 2():18-25
[PubMed PMID: 24443063]
[28]
Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. The New England journal of medicine. 2005 Dec 8:353(23):2450-61
[PubMed PMID: 16339094]
[30]
Zhu B, Liu B, Tang G, Jin P, Liu D. Two cases report of febuxostat-induced acute liver injury: acute heart failure as a probable risk factor? Drug and chemical toxicology. 2024 Jan:47(1):55-59. doi: 10.1080/01480545.2023.2178451. Epub 2023 Feb 14
[PubMed PMID: 36789513]
Level 3 (low-level) evidence
[31]
Chou HY, Chen CB, Cheng CY, Chen YA, Ng CY, Kuo KL, Chen WL, Chen CH. Febuxostat-associated drug reaction with eosinophilia and systemic symptoms (DRESS). Journal of clinical pharmacy and therapeutics. 2015 Dec:40(6):689-92. doi: 10.1111/jcpt.12322. Epub 2015 Sep 14
[PubMed PMID: 26365588]
[32]
Han P, Hu L. Febuxostat-Induced Toxic Epidermal Necrolysis. American journal of therapeutics. 2022 Nov-Dec 01:29(6):e710-e712. doi: 10.1097/MJT.0000000000001256. Epub 2020 Oct 1
[PubMed PMID: 33021532]
[33]
Schumacher HR Jr. Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout. Expert opinion on investigational drugs. 2005 Jul:14(7):893-903
[PubMed PMID: 16022578]
Level 3 (low-level) evidence
[34]
Zeng XX, Tang Y, Hu K, Zhou X, Wang J, Zhu L, Liu J, Xu J. Efficacy of febuxostat in hyperuricemic patients with mild-to-moderate chronic kidney disease: a meta-analysis of randomized clinical trials: A PRISMA-compliant article. Medicine. 2018 Mar:97(13):e0161. doi: 10.1097/MD.0000000000010161. Epub
[PubMed PMID: 29595642]
Level 1 (high-level) evidence
[35]
Mikuls TR, Cheetham TC, Levy GD, Rashid N, Kerimian A, Low KJ, Coburn BW, Redden DT, Saag KG, Foster PJ, Chen L, Curtis JR. Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial. The American journal of medicine. 2019 Mar:132(3):354-361. doi: 10.1016/j.amjmed.2018.11.011. Epub 2018 Nov 29
[PubMed PMID: 30503879]
Level 1 (high-level) evidence
[36]
Deng JH, Lai PH, Xie LS, Qiu SS, Qiu DS, Zhang JX. Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta-analysis. Clinical and translational science. 2024 Mar:17(3):e13757. doi: 10.1111/cts.13757. Epub
[PubMed PMID: 38488426]
Level 1 (high-level) evidence
[37]
Ghossan R, Aitisha Tabesh O, Fayad F, Richette P, Bardin T. Cardiovascular Safety of Febuxostat in Patients With Gout or Hyperuricemia: A Systematic Review of Randomized Controlled Trials. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2024 Mar 1:30(2):e46-e53. doi: 10.1097/RHU.0000000000002045. Epub 2023 Dec 20
[PubMed PMID: 38115182]
Level 1 (high-level) evidence
[38]
Hu S, He S, Zhang J, Ma W, Geng H, Zhan Z, Yao X, Zhong L, Wei J, Qiu X, Jia E. Association between patient adherence and treat-to-target in gout: A cross-sectional study. Medicine. 2024 Feb 23:103(8):e37228. doi: 10.1097/MD.0000000000037228. Epub
[PubMed PMID: 38394537]
Level 2 (mid-level) evidence